Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Serine hydroxymethyltransferase 2 expression promotes tumorigenesis in rhabdomyosarcoma with 12q13-q14 amplification
Thanh H. Nguyen, … , Wenyue Sun, Frederic G. Barr
Thanh H. Nguyen, … , Wenyue Sun, Frederic G. Barr
Published June 24, 2021
Citation Information: J Clin Invest. 2021;131(15):e138022. https://doi.org/10.1172/JCI138022.
View: Text | PDF
Research Article Cell biology Oncology Article has an altmetric score of 3

Serine hydroxymethyltransferase 2 expression promotes tumorigenesis in rhabdomyosarcoma with 12q13-q14 amplification

  • Text
  • PDF
Abstract

The 12q13-q14 chromosomal region is recurrently amplified in 25% of fusion-positive (FP) rhabdomyosarcoma (RMS) cases and is associated with a poor prognosis. To identify amplified oncogenes in FP RMS, we compared the size, gene composition, and expression of 12q13-q14 amplicons in FP RMS with those of other cancer categories (glioblastoma multiforme, lung adenocarcinoma, and liposarcoma) in which 12q13-q14 amplification frequently occurs. We uncovered a 0.2 Mb region that is commonly amplified across these cancers and includes CDK4 and 6 other genes that are overexpressed in amplicon-positive samples. Additionally, we identified a 0.5 Mb segment that is only recurrently amplified in FP RMS and includes 4 genes that are overexpressed in amplicon-positive RMS. Among these genes, only serine hydroxymethyltransferase 2 (SHMT2) was overexpressed at the protein level in an amplicon-positive RMS cell line. SHMT2 knockdown in amplicon-positive RMS cells suppressed growth, transformation, and tumorigenesis, whereas overexpression in amplicon-negative RMS cells promoted these phenotypes. High SHMT2 expression reduced sensitivity of FP RMS cells to SHIN1, a direct SHMT2 inhibitor, but sensitized cells to pemetrexed, an inhibitor of the folate cycle. In conclusion, our study demonstrates that SHMT2 contributes to tumorigenesis in FP RMS and that SHMT2 amplification predicts differential response to drugs targeting this metabolic pathway.

Authors

Thanh H. Nguyen, Prasantha L. Vemu, Gregory E. Hoy, Salah Boudjadi, Bishwanath Chatterjee, Jack F. Shern, Javed Khan, Wenyue Sun, Frederic G. Barr

×

Figure 6

Effect of SHMT2 knockdown on Rh30 cell growth and transformation.

Options: View larger image (or click on image) Download as PowerPoint
Effect of SHMT2 knockdown on Rh30 cell growth and transformation.
(A) Qu...
(A) Quantitation of SHMT2 mRNA expression by qRT-PCR in control and SHMT2 shRNA-expressing Rh30 cells. GAPDH was used for normalization. Data are represented as mean ± SD of 3 replicates. (B) Western blot analysis of SHMT1 and SHMT2 expression in control or shRNA-expressing cells. GAPDH was used as loading control. (C) Measurement of NADPH cellular levels in control and shRNA-expressing cells. Data are represented as mean ± SD of 3 replicates. (D) IncuCyte growth assay. Data are represented as mean confluence ± SEM of 4 different wells. (E) Clonogenic assay: 360 cells were seeded in 6 cm dishes, cultured for 3 weeks, then fixed and stained with Giemsa. (F) Focus formation assay: 500 cells were cocultured with 2 × 105 NIH 3T3 fibroblasts in 6-well dishes for 3 weeks, then fixed and stained with Giemsa. (G) Intramuscular xenograft tumor formation of Rh30 cells. All tumors (5 mice per group) were excised when the largest tumor reached the maximum size permitted. (H) Xenograft tumor growth. Tumor sizes were measured twice weekly, and tumor volume was calculated as (width2 ×length)/2. Data are shown as mean volume ± SD of 4 mice per group. For A and C, Dunnett’s multiple comparisons test was used for statistical analysis. *P < 0.0001 (A); *P < 0.01 (C). For D, ANOVA tests (corrected for multiple comparisons using the Šidák-Bonferroni method) were performed for the last 6 time points. *P < 0.05, adjusted. For H, Student’s t test (2 tailed, type 2) was used for statistical analysis. *P < 0.05. Experiments in A, B, D, E, and F were repeated at least 3 times, and representative data are shown. Results shown in G and H were derived from separate independent experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 5 X users
8 readers on Mendeley
See more details